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Abstract. This review covers recent developments in the area of particle engineering via spray drying.
The last decade has seen a shift from empirical formulation efforts to an engineering approach based on a
better understanding of particle formation in the spray drying process. Microparticles with nanoscale
substructures can now be designed and their functionality has contributed significantly to stability and
efficacy of the particulate dosage form. The review provides concepts and a theoretical framework for
particle design calculations. It reviews experimental research into parameters that influence particle
formation. A classification based on dimensionless numbers is presented that can be used to estimate
how excipient properties in combination with process parameters influence the morphology of the
engineered particles. A wide range of pharmaceutical application examples—low density particles,
composite particles, microencapsulation, and glass stabilization—is discussed, with specific emphasis on
the underlying particle formation mechanisms and design concepts.
KEY WORDS: dispersibility; microencapsulation; particle formation; respiratory drug delivery;
stabilization.
INTRODUCTION
Many solid dosage forms in the pharmaceutical and
biotech industries are based on microparticles. Dry powders
are inhaled as aerosols into the lung, delivered to the nose,
filled into capsules, or pressed into tablets for oral applica-
tions, or even delivered transdermally. In the past, micro-
particles were often viewed simply as carriers, usually
micronized dry material, without sophisticated attributes.
The primary functions of the micronization and drying
processes were to achieve a suitable particle size and remove
most of the solvent. This perspective has changed as novel
drug delivery strategies were developed. More advanced
therapeutic approaches have created complex requirements
for dosage forms that can only be met by particles that are
designed for a range of functions such as stabilization of the
active, transport and targeting of the dose, or release
modulation. The particle is no longer seen as a passive carrier,
but rather as an essential part of the drug delivery system.
Particle Engineering is a young discipline that combines
elements of microbiology, chemistry, formulation science,
colloid and interface science, heat and mass transfer, solid
state physics, aerosol and powder science, and nanotechnol-
ogy. It provides the theoretical framework for a rational
design of structured microparticles. Particle engineering
requires a deeper understanding of particle formation pro-
cesses. Complex structured microparticles are difficult to
design using an empirical approach alone because of the
many process and formulation variables that need to be tuned
correctly to achieve the desired result.
Efforts to understand and control particle formation
processes were intensified in the last decade, coinciding with
the development of pulmonary therapeutics that were tradi-
tionally given by injection (1–3). The pulmonary route was
found to be viable for systemic delivery of proteins and
peptides (4–6), in particular insulin (7–18), triggering the
development of diverse administration systems and particle
engineering strategies (19–28).
Microparticles can be manufactured by many different
processing methods. This review focuses exclusively on spray
drying (29–35), with an emphasis on the literature of the last
five years. Wet chemistry and phase separation processes and
alternative drying processes such as spray freeze drying, or
supercritical fluid technologies, have also been used widely
for particle engineering purposes and have been reviewed
elsewhere (36–41).
DEFINITIONS AND THEORY
The purpose of this section is to clarify the terminology
needed for a discussion of particle engineering. It will also
provide equations that can be used to describe particle
properties and the particle formation process. A rigorous
treatment of the physics and chemistry that form the
foundation of particle engineering is beyond the scope of this
review and the reader is referred to several textbooks (29,42–
45) that cover this material in more detail. Rather, this section
will focus on working equations that can be used to link
material properties and process parameters to particle,
aerosol, or powder properties and the resultant product
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pearltherapeutics.com)attributes. An engineering approach is used, relying on
dimensionless numbers, and approximate expressions are
presented where the exact equations are cumbersome to use.
Terminology of Structured Microparticles
Particle morphology can be described in terms of particle
size, shape, internal structure, and surface properties. The
terminology used in the literature to describe structured micro-
particles is inconsistent; this review suggests the following:
A core is the innermost part of the particle. It can be
covered by one or more layers that are defined by having
distinct composition or properties. A shell is an outer layer
that is capable of bearing enough mechanical stress to
influence or determine the morphology of the particle. In
contrast, a coat is a thin layer incapable of providing
structural rigidity. The schematic in Fig. 1b shows an idealized
layered sphere with internal structure, comprising a core, a
second layer, a shell and a coat. In Fig. 1a the core is replaced
with a central void.
Particles can also have the cellular structure of solid
foams, shown schematically in Fig. 1c and e. In contrast to
voids, which are simply gas-filled space, cells are defined by a
surrounding layer such as a membrane. Foam physics
terminology can be used to describe the characteristics of
the cellular material: in the case of a closed cell structure
(Fig. 1c) the membranes of adjoining cells remain mostly
intact, while in an open cell structure (Fig. 1e) the membranes
have ruptured, leaving a network of struts behind which are
called Plateau borders. The cells can be described as the
dispersed phase and the interstitial matter between the cells
as the continuous phase. Colloid science terminology is also
applicable to particles that were created from suspensions of
solids. Fig. 1d and f show schematic examples where the
dispersed phase consists of smaller solid particles, typically
nanoparticles. Two cases of particles are shown; a carrier
particle where a significant fraction of the particle mass is in
the continuous phase with few embedded smaller particles,
and the opposite case of a particle with most of the mass in
the dispersed phase. In the latter case the nanoparticles have
formed a composite shell. A large number of small, homoge-
nously dispersed, solid nanoparticles give the particle the
nature of a sol. Embedded nanoparticles or liquid nano-
droplets may have a coat or membrane at the solid–solid or
liquid–solid phase interface. The latter case, a gel particle, is
often called a dry emulsion in the literature (46–48). Fig. 1g
shows a particle with internal composition gradients which
has an irregular surface forming external voids. The term
irregular is used for particles whose primary form deviates
significantly from that of a perfect sphere, such as indented or
wrinkled particles. Irregular particles may still be spherical, i.e.
their aspect ratio may be close to one.
Particle Size
With few exceptions, spray dried particles are spherical
and their size can be described by their geometric diameter.
This is an important parameter which influences the forces
particles experience in fluid flows and the packing of particles
when they form a powder. The geometric diameter is also
often used as a reference, because it is in principle directly
accessible by ultramicroscopic techniques.
However, the measurement of geometric diameters by
image analysis is not without difficulties. One is rarely
interested in the size of just a single particle, but rather the
size distribution of all particles in a product. In the context of
pharmaceutical applications the mass fraction of a particulate
dosage form in a certain particle size interval is often sought.
This information can be obtained by image analysis of a
sample of the dose, but care has to be taken to ensure that a
representative, statistically relevant sample is analyzed.
Usually, this can only be accomplished with the help of
automated microscopya n di m a g ea n a l y s i s( 49). Image
analysis techniques generate count-based distributions that
have to be converted to a mass-based distribution, e.g. with
the help of the Hatch Choate equations (44).
The geometric diameter of particles that are not perfect
spheres depends on their orientation. In this case an average
geometric diameter can be substituted, e.g. by averaging
Feret’s horizontal and vertical diameters (50). If this is carried
out on a large number of particles that are randomly oriented,
the reported geometrical diameter is the orientation averaged
Feret’s diameter.
Other common particle sizing techniques do not measure
the geometric diameter directly, but rather derive it from the
behavior of the particles in response to the probe used in the
analysis. The reported diameters are often confused with
geometric diameters, but are in fact equivalent diameters
specific to the analytical technique (49). A common example
is an optical-equivalent diameter where particles are probed
by a light source. Their scattering or absorption behavior is
compared to that of a reference geometry, usually a
homogeneous sphere. The geometric diameter of the refer-
ence sphere is only representative of the diameter of the
sample particle if the optical properties of the sample are
close to that of the reference. For structured or irregularly
shaped particles this is often not the case, as can easily be
recognized considering the variety of particle types shown in
Fig. 1. The optical particle size for these particles is in reality
a function of their geometric diameter and their secondary
morphological features (51,52). Equivalent particle diameters
based on other properties or behavior such as electrical
mobility, diffusion, sedimentation, surface or volume to
surface ratio are used frequently and are described in the
literature (49,53).
An equivalent diameter of particular importance to
respiratory delivery is the aerodynamic diameter, i.e. the
Fig. 1. Schematic representation of particle morphologies. a Layered
with central core. b Layered with central void. c Solid foam, closed
cell. d Solid foam, open cell. e Particle with embedded nanoparticles.
f Composite shell. g Irregular, with external voids and internal
concentration gradients.
1000 Vehringdiameter of a unit-density sphere that has the same settling
velocity as the measured particle.
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Equation 1 is a simplified description, valid for spheres in
the continuum regime. Treatment and corrections for non-
sphericity and transition regime flow can be found in the
aerosol science literature (44,49,54). The particle density, ρP,
in this equation should not be mistaken for the true density of
the dried material. The particle density is the mass of the
particle divided by the volume of a sphere of diameter dg and
can be significantly lower than the true density, because it
includes internal and external voids.
It is straightforward to express the geometric diameter of
spray dried, spherical particles as a function of formulation
and process variables. The geometric diameter of the dry
particle follows from a simple mass balance (55)
dg ¼ 3
ﬃﬃﬃﬃﬃﬃ
cF
 P
r
dD ð2Þ
This equation shows that the geometric diameter can be
most effectively controlled by the atomization which deter-
mines the diameter of the droplets, dD. Particle size is also
directly affected by changes in the concentration of the feed
solution, cF. If Eqs. 1 and 2 are combined the resulting
expression
da ¼ 6
ﬃﬃﬃﬃﬃﬃ  P
 *
r
3
ﬃﬃﬃﬃﬃﬃﬃ
cF
 *
s
dD ð3Þ
shows that the aerodynamic diameter is also primarily deter-
mined by the feed solution concentration and the initial droplet
diameter. Although somewhat counterintuitive, it is only a weak
function of particle density, whicho n l yb e c o m e si m p o r t a n ti fi ti s
significantly lower than unit-density. This explains the current
trend to particles of very low density on the order of 0.1 g/cm
3 in
pulmonary delivery, where a small aerodynamic diameter is
desirable. Equation 3 also cautions that changes in the droplet
size distribution, which may be encountered during process
scale-up, or increases in the feed concentration, often initiated
to improve the economics of the process, can cause a significant
change in the aerodynamic properties of the particles.
Atomizer performance directly influences the particle
size of the dried particles. Four different types of atomizers
are used for the majority of industrial spray drying applica-
tions; rotary atomizers, pressure nozzles, two-fluid nozzles
(29,56), and ultrasonic atomizers (57,58). Typical droplet mass
median diameters in pharmaceutical spray dryers range from
less than 10 μm for pulmonary applications to upwards of
100 μm, which translates to a typical dry particle diameter
range of 0.5 to 50 μm. Atomizer performance as a function of
solution properties and operating conditions has been de-
scribed elsewhere (29).
Distribution of Components in Spray Dried Particles
The key to successful particle engineering is understand-
ing and controlling the mechanisms that determine the radial
distribution of components during the drying process.
Several different driving forces that may be responsible
for separation of components have been suggested. Surface
activity may lead to preferential adsorption of components
on the droplet surface, causing a diffusional flux toward the
surface. On the other hand, as the evaporating droplet
shrinks its receding droplet surface leads to increasing
solute concentrations at the surface. This causes a diffu-
sional flux away from the surface (59). The diffusional
motion inside an evaporating droplet must be correctly
described to predict the resulting radial distribution of the
individual components.
The evaporation of a solution droplet in a spray dryer is
a coupled heat and mass transport problem. The process is
driven by the difference between the vapor pressure of the
solvents and their partial pressure in the gas phase. The rate
of evaporation is determined by the balance of energy
required to vaporize the solvent and the energy transported
to the surface of the droplet. Various numerical models have
been presented and reviewed (60–62)t h a td e s c r i b et h e
evaporation of multicomponent droplets in detail. Here a
simplified analytical treatment is summarized.
In the absence of internal convection the distribution of
the chemical components in an evaporating droplet can be
described by the non-linear diffusion equation. For constant
diffusion coefficients and negligible interactions between the
solutes the diffusion equation becomes Fick’s second law of
diffusion (42). This equation in its one-dimensional, radially
symmetric form has an analytical solution, if the droplet
evaporates at a constant evaporation rate (63). The evapora-
tion rate, κ, is defined as (43,64)
d2 t ðÞ¼d2
0    t ð4Þ
The droplet surface area decreases linearly with time.
This equation can also be used to approximate the droplet
drying time (64) which should be smaller than the residence
time of the droplets in the dryer to allow completion of
drying.
 D ¼
d2
0
 
ð5Þ
The solution of the diffusion equation can be rearranged
so that it yields the surface enrichment, Ei, which is the
surface concentration of component i in relation to its
average concentration in the droplet (50)
Ei ¼
cs;i
cm;i
¼
exp 0:5Pei ðÞ
3 i
; ð6Þ
Here a dimensionless Peclet number, Pe, has been used
to simplify the equation:
Pei ¼
 
8Di
ð7Þ
β is a function that must be integrated numerically for
each Pe number to obtain an exact solution (50). However, an
1001 Pharmaceutical Particle Engineering via Spray Dryingapproximate expression for Eq. 6 with an accuracy of ±1% in
the range Pe<20 can be used instead:
Ei ¼
cs;i
cm;i
¼ 1 þ
Pei
5
þ
Pe2
i
100
 
Pe3
i
4;000
ð8Þ
The average concentration follows from a mass balance.
cm;i ¼ c0;i 1  
t
 D
     3
2
ð9Þ
With these equations, the surface concentrations of the
components can be predicted at any time in the evaporation
process as a function of their Peclet number. A very useful
parameter, τsat,i, the time for a component to reach saturation
at the surface, can now be derived.
 sat;i ¼  D 1   S0;iEi
   2
3
  
ð10aÞ
S0;i ¼
c0;i
csol;i
; ð10bÞ
where the initial saturation of the components, S0,i, is the
second dimensionless parameter that directly influences the
particle formation process.
Components may not crystallize immediately when their
solubility limit is reached at the surface. Further characteristic
times are associated with crystal nucleation, crystal growth,
and polymorph transitions. For components that do not
readily crystallize these characteristic times are frequently
longer than the “precipitation window” defined by
 p;i ¼  D    sat;i ¼
d2
0
 
S0;iEi
   2
3: ð11Þ
In this case a fully or partially amorphous solid is formed.
Here another parameter becomes useful: τt,i, the time it
would take a component to reach a concentration at the
surface that is equal to its true density in the dry state. While
this is obviously a hypothetical case in a multi-component
droplet, this characteristic time can still be used for a rough
estimate of the time at which an amorphous shell at the
surface is formed.
 t;i ¼  D 1   P0;i   Ei
   2
3
  
; ð12aÞ
P0;i ¼
c0;i
 t;i
ð12bÞ
The characteristic times given above are useful for
particle design, because they allow an estimate of the
sequence of precipitation events at the surface and the time
that is available for crystallization of components. The
equations can only be evaluated if a reasonable estimate for
the droplet evaporation rate can be found. Calculation of
evaporation rates as a function of the processing parameters
is not a trivial problem in a realistic spray dryer. Here a
simple approximation is given that uses the following
equation (45) for single droplet evaporation
  ¼ 8Dg
 g
 l
Ys Te ðÞ   Y1 ðÞ : ð13Þ
Please see Table I for nomenclature. Although it neglects
Stephan flow (65), this expression is still a good approxima-
tion as long as the partial pressure of the evaporating solvent
remains small, i.e. for droplet temperatures that are much
lower than the boiling point of the solvent. At high droplet
temperatures the effects of Stephan flow should be included.
Adequate expressions for the latter case are given in the
literature (43,50,66). To find the mass fraction at the surface
of the droplet, Ys, the equilibrium temperature, Te, of the
evaporating droplet must be determined. This can be done by
iteratively solving the equation
$b Hv
^ cp
¼ 
Le   T1   Te ðÞ
Ys Te ðÞ   Y1
ð14Þ
in combination with a Clausius–Clapeyron relationship. The
Lewis number, Le, is the ratio of the thermal diffusivity and
the mass diffusivity in the gas phase (42). However, in the
most common case of droplets evaporating in dry air or
nitrogen the iteration can be avoided and the problem
becomes very simple. A useful first approximation for the
equilibrium temperature is an empirical correlation (60) for
the wet bulb temperature of the droplet as a function of gas
temperature, TG, and boiling temperature of the solution, Tb.
Twb ¼ 137
Tb
373:15
   0:68
log TG ðÞ   45 ð15Þ
Once the droplet temperature is determined, the vapor
pressure or mass fraction at the surface of the droplet can be
foundusinganAntoineequation(50) or tabulated data. Finally,
the evaporation rate follows according to Eq. 13, and the
Peclet numbers and the characteristic times for the components
can be calculated. Frequently, no data is available for the
diffusion coefficients of the solutes, but an estimate based on
the Stokes–Einstein equation is usually sufficient.
Several corrections, e.g. for droplet–droplet interactions
or for convective flow around the drying droplets would need
to be introduced to describe the actual situation in a spray
dryer. Adequate models describing droplet evaporation in
spray dryers have been developed in combustion research
(67) and the food industry (68,69). Modeling of flow fields in
spray dryers has been accomplished (34). The usefulness of
the simple approach presented here lies in its potential to
provide a quick overview of general trends for a particular
particle design problem. It allows an assessment of the
relative importance of various process parameters and
material properties. This treatment cannot describe the
processes that occur during the solidification of the particles,
such as precipitation or buckling of shells (70), and it does not
account for surface activity. However, it can approximate the
radial distribution of all components prior to solidification.
This may be predictive of the structure of the dry particle, as
has been pointed out in an excellent study on the drying of
1002 Vehringmilk powder (59). Hence, this model allows an estimate of
which component is likely to act as a shell former.
A comprehensive theoretical description of particle
formation during spray drying has not been published. The
drying process of micro-droplets proceeds through non-
equilibrium states where material properties are frequently
unknown and experimentally difficult to access. Therefore,
much of what is known about microparticle drying has been
derived experimentally. It is worthwhile to review the
experimental techniques that have been used to study droplet
evaporation and particle formation. When interpreting the
results of these studies it is important to consider the inherent
limitations of the particular methods.
PARTICLE FORMATION
Experimental Techniques
Various experimental techniques for the investigation of
droplet drying and particle formation have been introduced.
Studies using actual processing equipment are difficult to
execute and interpret, because of the complexity of the two-
phase flow in spray dryers, the difficulty of installing adequate
analytical instrumentation into a development dryer, and the
large number of processing and formulation variables. Conse-
quently, most of the techniques study more or less simplified
systems that are models of the actual situation in a dryer.
Arguably the most simplified system is a single droplet in
quiescent gas. Various levitation techniques, using optical,
acoustic, or electrodynamic forces can be used to freely levitate
single microdroplets (71,72). Non-contact probing of the
evaporating droplets allows measurement of evaporation rates
with minimal interference. The shortcoming of the technique is
in the time-scales that can be probed. It is difficult to introduce
and levitate microdroplets in the experimental apparatus
quickly enough to allow observation of a phenomenon with a
characteristic time on the order of 10 ms. Most studies on freely
l e v i t a t e dd r o p l e t sh a v eu s e de i t h e rl a r g e rd r o p l e t so rl i q u i d s
with very low vapor pressure that evaporate so slowly that the
initial droplet capture and stabilization becomes short compared
to the time of the measurement. A second disadvantage of this
method is that shrinking and solidifying droplets experience a
significant change in properties such as refractive index, charge
state, or sphericity. This can lead to difficulties in maintaining a
stable levitation until the end of the evaporation process.
An interesting variant of single droplet levitation uses the
Leidenfrost phenomenon to trap droplets on a concave hot
plate (70,73). This technique was successfully used to study shell
buckling during particle formation. A drawback of this approach
is that the flow and temperature fields near the droplet are not
similar to those of a free flowing droplet in a spray dryer.
The latter complication has been addressed by studying
droplets suspended from thin filaments. This technique was
used to observe the particle formation process of millimeter-
sized droplets; particle density and morphology as a function
of latent heat of crystallization, solubility, and drying rate
were investigated (74). A recent study used a similar
experimental set-up with an added capability to measure the
surface adhesion of single, partially dry particles as a function
of particle composition and moisture content (69). A refined
filament suspension technique was applied to monitor the
drying process of milk droplets (75–78). The morphology of
dried particles was studied using suspended droplets for more
than forty years (62,79–84), and much useful information has
been derived from these studies. However, the use of a
filament to suspend droplets has limitations. Heat and mass
transfer can be affected by heat conduction between droplet
and filament. The technique requires relatively large droplets,
typically in the millimeter diameter range. This is problematic,
because the processes involved in droplet drying scale
differently with diameter. Droplet behavior observed on
millimeter sized droplets may not be representative of micro-
droplets that are of interest in pharmaceutical applications.
Realistically sized droplets have often been studied in
small scale spray dryers (55,85). These studies have shed light
on many individual aspects of the drying process. The
importance of the ratio between droplet evaporation rate
and diffusional motion of the solutes was recognized and the
concept of the Peclet number has been used to explain low
density particle morphology (86). It was also found that feed
solution concentration (87) and solubility of the excipients
Table I. Nomenclature
Variable Definition
cF Feed solution concentration
c0,i Initial concentration, component i
cs,i Surface concentration, component i
csol,i Solubility, component i
cm,i Average concentration, component i
cp Specific heat capacity, solvent vapor
d Diameter
d0 Initial diameter
da Aerodynamic diameter
dD Droplet diameter
dg Geometric diameter
Ei Surface enrichment, component i
D Diffusion coefficient, liquid phase
Dg Diffusion coefficient, gas phase
Le Lewis number
P0 Initial density ratio
Pe Peclet number
t Time
Tb Boiling temperature
Te Equilibrium temperature, droplet
TG Drying gas temperature
Twb Wet bulb temperature
T1 Gas temperature far away from droplet
S0 Initial saturation
YS Mass fraction of solvent at surface
Y1 Mass fraction of solvent far from surface
$Hv Standard enthalpy change of vaporization
β Profile function
ρ* Reference density, 1 g/cm
3
ρt True density
ρP Particle density
ρg Drying gas density
ρl Droplet density
k Evaporation rate
τD Characteristic droplet drying time
τsat Characteristic time to saturation
τp Characteristic time for precipitation
τt Characteristic time to true density
1003 Pharmaceutical Particle Engineering via Spray Dryingaffect particle morphology (88–90). Several studies show that
precipitation kinetics and crystallization play an important
role and may be affected by evaporation rate (91,92). It has
also been pointed out that drying temperature has a strong
effect on particle morphology (93,94).
Some researchers have used a chain of monodisperse
free falling droplets to study heat and mass transfer, drying,
and particle formation processes (80,95–98). With this tech-
nique the effect of drying rates on particle formation and the
formation of internal voids in particles have been studied.
The droplet generator commonly used in this technique
produces closely spaced droplets, which may lead to drop-
let–droplet interactions (99–101), because the evaporation
process is determined by gas phase transport processes.
Furthermore, the studies were still carried out on relatively
large droplets with a diameter >170 μm( 102).
Recently, an improved droplet chain technique has been
introduced (50) that is based on a droplet-on-demand
generator. In this technique the droplet distance is a free
variable and can be chosen so that droplets do not measur-
ably interact. It is also capable of generating droplets in the
diameter range useful for respiratory delivery. Basic particle
formation mechanisms have been derived with this technique,
which are categorized in the next section.
Formation Mechanisms
Low Peclet number
For Peclet numbers smaller than 1, the diffusional motion
of the solutes is fast compared to the radial velocity of the
receding droplet surface. In the absence of other driving
forces, the solutes remain fairly evenly distributed in the
droplet during the evaporation. The surface enrichment is
small. If the solutes are freely soluble in the solvent, the initial
saturation is also small and the characteristic time for the
solutes to reach saturation at the surface is close to the droplet
lifetime. In this case, solid particles with a particle density close
to the true density of the dry components are likely to form.
Typical examples are solid saccharide particles (103) dried at
moderate to low drying gas temperatures, as shown in Fig. 2.
The Peclet number is influenced by a combination of
material properties of the solute and the solvent and
processing parameters that determine the evaporation rate.
Even small molecules with comparatively large diffusion
coefficients can be forced into significant surface enrichment
with sufficiently large evaporation rates.
Evidence for this can be found in hollow lactose particles
that were dried in a bench-top spray dryer at relatively high
inlet temperatures (88,104,105). The processing parameters
reported by the authors suggest a Peclet number larger than
1, which is indicative of the particle formation mechanism
described in the next section.
High Peclet Number
In the case of Peclet numbers larger than 1, schematically
shown in Fig. 3, the surface moves faster than the dissolved or
suspended components. The result is that the surface
becomes enriched with the component associated with the
high Peclet number. Depending on the nature of the
component, different solidification mechanisms are triggered
once a critical concentration at the surface is reached. Solutes
may not have sufficient time to crystallize during the
precipitation window. Instead, a shell may be formed due to
the increase in viscosity as the solution transitions to a wet
glass at the surface. Molecules with high initial saturation and
fast crystallization kinetics may separate into a crystalline
phase. Suspended material may form a composite shell.
Regardless of the nature of the shell formation mechanism,
the process is initiated at the surface. The resulting particles
can have a range of different morphologies, depending on
their size and the properties of their shells in the final stages
of the drying process. Solid hollow spheres can be formed, if
the shell becomes rigid quickly and does not buckle or fold.
Otherwise, dimpled or wrinkled particles are formed.
The change of morphology as a function of Peclet
number for a glycoprotein dried in a droplet chain technique
is shown in Fig. 4. With increasing Peclet numbers the time to
reach the critical concentration for shell formation at the
surface decreases, i.e. shell formation occurs earlier in the
evaporation process on a larger droplet. Hence, the density of
the particle decreases.
Typical examples that fall into the category of high Peclet
number particle formation are proteins and polymers. There
are numerous examples in the literature reporting hollow and
wrinkled or dimpled morphologies for spray dried protein
(50,92,106–110), peptide (111,112)o rp o l y m e rp a r t i c l e s
(57,90,113–118). An extreme case is the drying of droplets
that contain suspended material such as nanoparticles
(86,119). Compared to the receding droplet surface the
suspended material can be considered as immobile. The
resulting surface accumulation and formation of a thin shell
are intuitive in this case.
Fig. 2. Morphology of trehalose particles, spray dried from a custom
benchtop spray dryer with monodisperse atomizer at drying rates
between 1.7 and 4.1 μm
2/ms. The particle on the right was
intentionally crushed to reveal its internal structure.
Fig. 3. Proposed particle formation process for high Peclet numbers.
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The discussion inthe preceding section isverysimplified.It
assumes a constant evaporation rate and a diffusion coefficient
that does not change with time or location in the droplet. In
reality, the diffusion coefficient of a component changes with
concentration and composition of thesolvent. Hence,the Peclet
number changes as the droplet evaporation progresses, in
particular in co-solvent systems, where one solvent evaporates
faster than the other. The Peclet number associated with a
component in a formulation system can also change drastically,
when the component undergoes a phase transition, e.g.
crystallizes once a critical concentration is reached. This case is
shown schematically in Fig. 5. Here a molecule with low
solubility is dried that has a large diffusion coefficient, so its
Peclet number is low initially. The concentration increases
without much surface enrichment until supersaturation is
reached and precipitation of a separate phase is initiated at
the surface or throughout the bulk of the droplet. At this point
the mobility of this component is no longer determined by the
diffusion coefficient of the dissolved molecule, but rather by
the much lower mobility of the phase separated domains. The
Peclet number associated with this component is now very
large and the phase separated domains accumulate at the
surface and merge to form a shell which may deform in various
ways, subsequently. Typical excipients that fall into this class
are low solubility amino acids or small peptides that have a
propensity to crystallize or form liquid crystals.
A striking example for this type of formation mechanism
is shown in Fig. 6. The electron micrograph shows hollow
sodium chloride particles that were spray dried with an initial
saturation of about 0.3 (120,121). The size of the salt crystals
in the shell corresponds to the diameter of the dry particle.
This indicates that the precipitation window is shorter for
smaller droplets, and the crystals do not have time to grow to
the same size as in the larger droplets (see Eq. 11).
Open Questions
Many questions regarding the details of particle forma-
tion in spray drying remain unanswered. What is the role of
surface activity in shell formation? Can shell deformation be
Fig. 4. Morphology of monomorph, monodisperse glycoprotein particles, produced by a droplet chain technique in dry air at drying
temperatures of 25, 50, and 125°C, from left to right, corresponding to Peclet numbers of 2.7, 5.6, and 16.8 respectively.
Fig. 5. Proposed particle formation process for changing Peclet
numbers.
Fig. 6. Spray dried NaCl particles (With kind permission of
AktivDry, Inc., Boulder, CO).
1005 Pharmaceutical Particle Engineering via Spray Dryingcontrolled? Do microdroplets boil and inflate at high drying
gas temperatures?
It has been pointed out many times that surface active
molecules can replace other formulation components at the
droplet surface and are detected in increased concentration at
the surface of the dry particle (122–133). It was also shown
that the addition of small amounts of surface active material
can affect the particle morphology (108). Many of these
studies have used Electron Spectroscopy for Chemical
Analysis (ESCA) to analyze the surface composition of the
dry particles. Because the penetration depth of ESCA is on
the order of only 5 nm (134), it cannot be decided whether
the predominant material on the surface identified by ESCA
has formed a shell or has simply coated the particle. Other
methods capable of probing the sub-surface composition,
such as selective extraction of surface components or confocal
microscopy, are being explored (135). Recently, it has been
shown that the addition of a small amount of a surface active
molecule, trileucine, improves the dispersibility of particles
without changing the morphology of the particle (136). This
indicates a coat on the surface affecting the cohesiveness of
the particles. A larger amount of trileucine corresponding to a
high initial saturation of 0.25 was necessary to change the
morphology of the particle, which is in line with the formation
mechanism shown in Fig. 5. The presence of an ordered
surface layer may initiate or shorten the precipitation of the
supersaturated solute and thus indirectly affect the particle
morphology. However, it is not clear whether a surfactant
with high solubility, dried at low Peclet numbers, is capable of
forming a shell by a different mechanism than the ones
described above. In summary, there is currently no consensus
on the roleof surface active materialinparticleformation (133).
After a shell has formed on an evaporating droplet, it is
likely to be deformed by stress, due to pressure differences
(73) and changes in material properties caused by desiccation
or phase transformations. This period of the particle forma-
tion process determines whether a dry particle remains a
hollow sphere, forms dimples, or folds on itself. Because the
type of morphology affects important particle and powder
properties such as cohesiveness or dispersibility (107,137,138),
it is desirable to understand and control shell deformation
mechanisms. Theoretical approaches have been presented that
describe the buckling of shells composed of nanoparticles (70)
and the elastic deformation of polymer crusts on sessile drops
(139). However, there is currently no comprehensive theo-
retical model and few experimental studies (140) to describe
the shell deformation process on evaporating droplets in
general. Studies are complicated by a severe lack of material
properties in non-equilibrium states and the inability of
current experimental methods to probe the process on
realistic time and size scales.
It has been reported in the food drying literature (82)
that large particles dried at gas temperatures above the
boiling point of the solvent may inflate after shell formation
due to build-up of internal gas pressure, potentially causing
shell rupture or “blow-holes” in the shells. The author is not
aware of any studies that directly observe this mechanism on
droplets with a diameter on the order of 10 μm. Fig. 4
contains examples of particles dried above and below the
boiling temperature of the solvent. Notably, the type of
morphology does not change abruptly but rather continues a
gradual trend to lower density. The associated optical size
measurements show no evidence of inflation after shell
formation (50). It can be concluded that the hole visible in
these particles is not a “blow-hole” but rather a “sink-hole”
causedbythedryingofthedropletinterior.Itisunclearwhether
surface layers on small droplets pose sufficient diffusional
resistance to impede evaporation enough so that the droplet
temperature increases beyond the boiling temperature of the
solvent. Even if that was the case, it is unclear whether droplet
lifetimes on the order of milliseconds allow enough time for
bubble nucleation. In addressing this question the size of the
droplets and the scale of the spray dryer have to be considered
carefully. This issue points to an inherent complication in spray
drying; scale-up is not straightforward and may have significant
effects on the morphology of the particles.
APPLICATION EXAMPLES
Density Control
Low density or hollow particles are advantageous for
several applications, but specifically for pulmonary drug
delivery where they improve dispersibility and delivery
efficiency by lowering the aerodynamic diameter of the
particles. Several particle design strategies have been devel-
oped to create voids in particles to lower the density. A
hollow sphere can be created by using a shell forming
excipient in combination with suitable processing conditions
as described above. Irregular spherical particles may have
external void space in folds or dimples. A corrugated surface
further assists in dispersibility by minimizing contact areas.
The design of such wrinkled particles is reviewed in the next
section and creation of internal void space by alternative
methods in the following paragraphs.
Folded Shells
Internal and external void space can be created by
process conditions and formulations that cause early separation
of a soft surface layer, which folds to form a wrinkled
morphology. Early shell formation can be forced by choosing
a high initial saturation, a high Peclet number, or a combina-
tion of both for the shell former.
The prominent formulation system in this class is known
under the label “Large Porous Particles.” The concept was
introduced with polymer particles made by double- and
single-emulsification solvent evaporation procedures followed
by a freeze-drying step (141). Later the term “Large Porous
Particles” became associated with particles that consist of
dipalmitoylphosphatidylcholine (DPPC) in combination with
albumin and saccharides spray dried from a sub-azeotropic
ethanol–water co-solvent system (142–146).
DPPC has a very low aqueous solubility of 5 μg/ml or
less (146) and its initial saturation can be adjusted by the
ethanol water ratio. During the evaporation the DPPC
saturation increases faster than the saturation of hydrophilic
formulation components due to the preferential evaporation
of ethanol and the associated change in the co-solvent ratio
with time. The diffusion coefficient of DPPC is also low, in
particular when it assembles into organized lipid structures.
These properties point to a very early shell formation, which
1006 Vehringcan be achieved on a comparatively large droplet, because the
system is characterized by a low feed solution concentration,
typically 0.1% w/v (142). Hence, the resulting particles have a
very low particle density of typically less than 0.1 g/cm
3.
The experimental evidence in the literature points to
DPPC as the primary shell forming excipient in this system.
ESCA showed that the surface of particles consisting of
albumin, DPPC and a saccharide was enriched in DPPC
(147). Surface enrichment was reduced and particle density
increased when the co-solvent ratio was shifted to higher
ethanol content. This increased the solubility of DPPC which
may have led to a decrease in initial DPPC saturation,
delaying shell formation according to Eq. 10a, b. DPPC was
capable of forming low density particles without the presence
of albumin (86,147–149). Removing DPPC from the formu-
lation system led to denser particles (149).
It was shown, however, that the amount of albumin in
the formulation also has an effect on the morphology and
density of the particles (142,149). Albumin can change particle
morphology and lower particle density (107,122,138,150,151)
and it can be expected that it has the potential to act as a shell
former on its own (85,132,152). Its low diffusion coefficient
leads to large Peclet numbers at typical drying gas temper-
atures. Which shell former dominates the particle formation
process depends on their characteristic times to reach a critical
surface concentration and their interactions. Particle engineer-
ing using this formulation system relies on a proper selection of
formulation and process variables, which affect the interaction
and particle formation mechanisms of albumin and DPPC.
Large Porous Particles based on the DPPC–albumin
formulation system have demonstrated excellent performance
in DPI applications for pulmonary drug delivery. Emitted
doses in the range of 90–100% from a passive dry powder
inhaler were reported (149,153–155). Total lung deposition
and dose variability were clearly superior compared to
conventional DPI systems (154). It was hypothesized that
DPPC may have membrane permeation enhancer properties,
leading to increased bioavailability for peptides (153). These
particles may further have the potential for sustained release
in the lung (143,145,146) due to the low aqueous solubility of
the DPPC or avoidance of macrophage uptake (156). A
variant of this formulation system, known as Lipid–Protein–
Sugar Particles, typically produces smaller particles by spray
drying DPPC, albumin, and lactose from an ethanol–water
co-solvent system. The primary role of the shell formers in
this case is not the reduction of density, but the encapsulation
of the active pharmaceutical ingredient. These particles have
been suggested for sustained release applications of injectable
therapeutics and anesthetics in various tissue targets (157–163).
Large Porous Particles are a part of the AIR® pulmo-
nary drug delivery system (164–166) and have entered late
stage clinical trials for insulin (167–169) and early human
studies for parathyroid hormone (155,170). They have been
used to formulate human growth hormone (153), heparin
(171), and small molecules such as albuterol sulfate (144),
para-aminosalicylic acid (148), or levodopa (172).
Solid Foam Particles
A different approach to designing particles with very low
particle density is to create a foam-like particle morphology.
The most advanced method in this category is trademarked
under the label PulmoSpheres™ (173,174). These particles
are produced by spray drying of an emulsion, in which the
dispersed phase typically has a submicron droplet size and
consists of a liquid that evaporates slower than the continuous
phase. The dispersed phase is stabilized by phospholipids
which hinder coalescence when the droplet shrinks due to the
evaporation of the continuous phase. As a result the droplet
stops shrinking when the nanodroplets of the dispersed phase
are closely packed. The phase interfaces form a foam-like
structure that desiccates and solidifies subsequently. Once the
liquid of the dispersed phase has evaporated, the space
occupied by the former nanodroplets remains as voids,
leaving a solid foam that provides the desired reduction in
particle density (175). An example is shown in Fig. 7.
A comprehensive theoretical description of the forma-
tion process for this type of particle has not been published.
Spray drying of emulsions has been an intensive area of
research in food science, specifically regarding the drying of
dairy products. However, a consensus about the mechanisms
of emulsion dehydration has not been reached (176). The
problem is complex, because several competing sub-processes
with similar time-scales need to be considered. The motion of
the emulsion nanodroplets causes convective flow in the
droplet, the problem cannot be treated as one-dimensional,
and momentum conservation cannot be neglected. Still, the
lack of diffusional mobility of the dispersed phase may play a
role in the particle formation. It has been reported (175,177)
that increasing concentration of the dispersed phase leads to
the formation of a central internal void of increasing volume,
which is consistent with the diffusion controlled particle
formation mechanism described above.
In the case of PulmoSpheres™ the dispersed phase
typically consists of perfluorooctylbromide (PFOB) (178,179)
stabilized with distearoylphophatidylcholine (179–181)o ra
similar phospholipid (175). The properties of the phospholipid
can be optimized using calcium chloride (179,181,182). The
active pharmaceutical ingredient is typically dissolved in the
continuous phase if it has sufficient aqueous solubility.
The continuous phase may also contain additional excipients
such as hydroxyethylstarch (183).
Fig. 7. PulmoSpheres™ solid foam particles.
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rated into the PulmoSpheres™ particles as smaller separate
crystalline particles. In the suspension-based PulmoSpheres™
manufacturing process (181,184), the active is dispersed in the
form of micro- or nanocrystals in the continuous phase of the
emulsion. This complex suspension is then spray dried and
particles are formed that either have the character of carrier
particles (180), if the crystals are small enough to be embedded
in the typical solid foam structure of the PulmoSpheres™,o r
are composite particles (184). In the latter case the phospholipid
has been shown to form a coat on the dispersed material which
provides improved dispersibility. Lipid coating of micronized
material can alternatively be achieved by spray drying from a
lipid solution in which the microcrystals are suspended (185).
PulmoSpheres™ were originally developed as ultrasound
contrast medium (186) and have been administered to the
lung by liquid instillation (187–189). They have been applied
to pulmonary delivery of several small molecules and
peptides (178–180) and have been suggested for vaccination
purposes (183,190,191), modulation of immune responses
(192) or immunoglobulin delivery (193). The performance
of these advanced particles in dry powder inhalers (178,180)
or metered dose inhalers (179,194,195) has been shown to
significantly exceed that of conventional dosage forms. In a
study on pulmonary delivery of tobramycin, the authors
found that the delivery of the active using PulmoSpheres™
was nine times as efficient as delivery by a nebulizer (178). A
study on budesonide reported a two-fold efficiency advantage
relative to a conventional powder formulation (180).
The PFOB used in the manufacturing process of Pulmo-
Spheres™ is often called a blowing agent, which is somewhat
misleading, because its boiling point is higher than that of
water. Hence, the role of this pore forming agent during the
formation process is more that of a placeholder. The use of
propellants with much higher vapor pressure than water as
the dispersed phase in a formulation system otherwise similar
to that of PulmoSpheres™ has been attempted (196). The
resulting particles also have very low particle density but
posses a morphology that is not foam-like. The formation
mechanism for these particles has not been described in detail.
A related approach is the use of volatile salts as pore
forming agents to create voids (197,198). Typical examples,
termed pore forming agents in the associated literature, are
ammonium carbonate (199) or ammonium bicarbonate (200).
The volatile salt can be added in various ways to the droplets,
as micronized solid in an organic solvent (199,201), dissolved
in water (202), or via the dispersed phase of a water-in-oil
emulsion (203). Typically, the continuous phase or the organic
solvent evaporates first, forming the initial particle morphol-
ogy which incorporates the solid salt. The volatile salt is then
sublimed, typically in a secondary drying or freeze drying
step. If the formulation system is compatible with high drying
gas temperatures, ammonium bicarbonate may also be
removed directly during the spray drying process, as it
sublimes at temperatures above 50°C (202).
Particles based on this formulation approach have been
developed by Acusphere, Inc. as ultrasound contrast agents
(203) and delivery vehicle for poorly soluble drugs (204). In
this embodiment the continuous phase consists of a polymer,
poly-lactide-co-glycolide or polyvinylpyrrolidone (200), and
optionally a lipid, such as diarachidoyl-glycero-phosphocholine,
dissolved in suitable solvents such as methylene chloride or
ethanol (200). The continuous phase may also contain the
active pharmaceutical ingredient. The dispersed phase is an
aqueous ammonium bicarbonate solution.
Microencapsulation
The term microencapsulation has been used in various
ways by researchers and developers in food and pharmaceu-
tical sciences. It often simply means that a substance is
incorporated into a microparticle and no further description
of the particle structure and its effect on the performance of
the product is attempted. While in the food industry
microencapsulation is often associated with retention of
flavor or aroma substances during drying and storage (205–
207), pharmaceutical applications usually apply microencap-
sulation to control the release, improve bioavailability, e.g.
through mucoadhesion (208–211), or to mask the taste of an
active pharmaceutical ingredient (212,213). The term micro-
encapsulation implies that particles have an outer layer that
contains or protects the interior, but this is only one among
several particle morphologies that have been reported.
Encapsulation in a wider sense can also be accomplished
with a homogeneous particle where the matrix itself delays
dissolution and release, or with composite particles, where
smaller embedded particles or capsules may be covered by
additional layers with a barrier function (114,214–216).
Modulating the release of volatile or soluble components
from a microparticle in the presence of an external driving
force is a difficult task. The release rate from a microparticle is
influenced by complex interactions between body fluids, the
encapsulant, and the encapsulated material (217). Dissolution,
erosion and diffusion of material in the particle not only
depend on material properties such as solubility and diffusion
coefficients, but also on the morphology of the particle. The
rate of diffusion through a layer of encapsulant, for example,
depends on its thickness and surface area. In the case of
microparticles the layer thickness tends to be variable and on
the order of 1 μm or less, and the specific surface area is very
large, in particular if pores are present. The small length scales
associated with microparticles favor rapid release or an
unacceptable burst effect unless the associated diffusion
coefficients and solubilities are very low. Hence, materials
investigated for microencapsulation of spray dried particles are
typically high molecular weight, slowly biodegradable polymers
such as polylactide (89,114,118,214,218–224), polylactide-co-
glycolide, polycaprolactone (219,225–228), carbomers (229),
and methacrylate copolymers (213,230–237), or polysaccha-
rides (238)s u c ha sc h i t o s a n( 215,216,229,239–257), cellulose
derivatives (132,213,215,216,229,237,243,245,258), and hyalur-
onan (238,259), or cross-linked proteins (260). Polylactide-co-
glycolide, PLGA, has been studied most intensively and has
been used to encapsulate small molecule (94,117,220,224,261–
273) and protein (58,219,274–280) therapeutics and various
antigens (218,223,227,281–287) for vaccination purposes.
Detailed reviews of different microencapsulation strate-
gies for the purpose of controlled release and adjuvanticity in
therapy and vaccination are available (33,249,288–295). This
review focuses on a different application of microencapsula-
tion; the use of shells or coats to improve the dispersibility of
powders for pulmonary delivery. One approach in particular
1008 Vehringhas attracted significant attention, the use of leucine and
trileucine as dispersibility enhancers.
Leucine and Trileucine Particles
Dispersibility is a powder property that still lacks a
commonly accepted definition or measure. It is used to describe
the degree of dispersion of a powder into individual particles or
agglomerates upon exertion of an external dispersion force, e.g.
an aerodynamic shear force, typically in a pulmonary delivery
device such as a dry powder inhaler. The degree of powder
dispersion is important, because it has significant impact on the
respirable dose administered to the patient. Many particle
parameters affect powder dispersibility; frequently mentioned
are size distribution, density, morphology, surface energy,
surface roughness, and surface hydrophobicity.
The traditional approach to improving the dispersibility of
cohesive powders is to blend them with carrier particles or
additives that modify the interparticle forces. Amino acids,
lecithin, chitosan and magnesium stearate have been suggested
for this purpose (115,296). Among the amino acids, leucine
stands out as particularly effective in improving flowability and
dispersibility of powder blends (297,298). Therefore, it appears
promising to incorporate dispersibility enhancers such as amino
acids (115,299,300), specifically leucine, into the particles of a
homogeneous powder to encapsulate cohesive material or
improve the surface properties of the particles.
The formation mechanism for leucine particles can be
derived from the published literature. Pure spray dried leucine
forms hollow particles of low density (301,302), demonstrating
that leucine is capable of forming a shell, i.e. it has the potential
to encapsulate if the particles are designed correctly. Leucine is
a weak surfactant (303) with a low molecular weight of
131.17 g/mol. The initial Peclet number for typical drying
conditions is small, because its diffusion coefficient in water or
ethanol is large. However, the solubility of leucine in water is
low, 22 mg/ml, and even lower in ethanol. Consequently, if the
initial saturation is sufficient, leucine is expected to reach
supersaturation early in the drying process. Leucine may then
crystallize, following the particle formation mechanism de-
scribed above in the section about changing Peclet numbers.
Further support for this hypothesis comes from the
finding that leucine is crystalline in spray dried pure leucine
particles (301,302), in particles consisting of leucine, a
chelating agent and optionally a lipid (202), and in leucine–
epinephrine particles (304). However, if the initial saturation
of leucine in the droplet is low, allowing another component
to precipitate sooner, the leucine crystallization is expected to
be inhibited, a case that was apparently encountered in a
study (305) where a small amount of leucine was added to
disodium cromoglycate at low initial leucine saturation of S=
0.02. No crystalline leucine was detected in this case. The
initial saturation of leucine is evidently important, as shown in
a study on tobramycin, where the dispersibility increased with
increasing leucine content (306). Leucine is capable of
encapsulating even large molecules such as polymers or
antibodies if its initial saturation is high enough. This can be
aided by spray drying from a water–ethanol co-solvent system
where the solubility of leucine can be adjusted by changing
the solvent ratio (307). An example of leucine-encapsulated
protein particles is given in Fig. 8. In the electron micrograph
below the initial leucine concentration, corresponding to an
initial saturation of 0.25, was sufficient to encapsulate the
immunoglobulin particles. The particles shown above also
contain a small amount of leucine, but the initial saturation of
0.09 was too low to change the morphology. The morphology
of these particles is identical to that of pure immunoglobulin
particles (not shown). This particle design concept has been
used to improve the dispersibility of or encapsulate a variety
of active pharmaceutical ingredients and vaccines, such as β-
estradiol (308), follicle stimulating protein (309), plasmid
DNA (310), or bacillus Calmette–Guérin vaccine (311).
The discussion above shows that encapsulation by
leucine relies on a high initial saturation. This can be achieved
in several ways that all have their specific disadvantages. A
high concentration of the feed solution provides high initial
saturation, but also increases the dry particle size, which is
undesirable for pulmonary administration. A large fraction of
leucine in the formulation can accomplish high initial
saturation at lower feed solution concentrations, but is
unfavorable for therapeutics that require a large dose,
because it leads to a high powder mass and a large excipient
Fig. 8. Spray dried immunoglobulin particles. Above uncoated,
below coated with leucine.
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water co-solvent system increases the complexity of the
processing equipment and may not be compatible with all
active pharmaceutical ingredients or other required exci-
pients. An alternative approach is the use of a shell forming
excipient that combines many properties of leucine with a
lower aqueous solubility. This insight has lead to an investi-
gation of di- and tripeptides as dispersibility enhancers and
trileucine has emerged as particularly useful.
Compared to leucine, trileucine has a higher surface
activity and a threefold lower solubility in water. It has been
shown that trileucine indeed improved dispersibility at much
smaller fractions in the formulation than a comparable
leucine formulation in albuterol and salmon calcitonin
formulations (312). Pure spray dried trileucine particles have
ultra-low particle densities on the order of 0.1 g/cm
3 or less
and the density does not depend strongly on the drying rate
(50). The typical morphology of pure spray dried trileucine
particles is shown in Fig. 9.
The morphology of raffinose, cromolyn, gentamicin, and
netilmicin particles was changed to a rugose, low density type
with the addition of only 15% trileucine (136,313). A key
difference between leucine and trileucine particles is that
spray drying of trileucine results in non-crystalline powders,
indicating that trileucine precipitates into an amorphous or
partially ordered phase (314). This gives trileucine the ability
to participate in the stabilization of the active pharmaceutical
ingredient, as has been demonstrated with human growth
hormone (315). The role of particle engineering in stabiliza-
tion of particulate dosage forms is discussed in more detail in
the next section.
Stabilization
Every pharmaceutical product must remain efficacious
and safe during its shelf life. For microparticle products this
requirement tends to be complex, because not only the active
and the excipients need to remain chemically stable, but also
the physical stability of the dosage form must be accom-
plished. Microparticles produced by spray drying are often in
an energetically unfavorable state, because of their large
surface area. Also, they frequently have not reached an
equilibrium state, because of the short characteristic times of
the drying process. Given sufficient mobility, microparticles
tend to convert to an energetically more favorable state,
either by crystallization (316–320), polymorph transition
(321), crystal growth, or fusion of particles (322). All of these
processes usually lead to product failure. Chemical stability
can be lost through many routes depending on the nature of
the active. Some adverse influences like light exposure or
moisture and oxygen induced reactions can be mitigated
through external protection, e.g. desiccants or oxygen scav-
engers. However, it is usually preferable to plan for chemical
stability during particle design. For degradation that is driven
by air–liquid interface exposure, aggregation, or unfolding of
proteins there is no other viable option. For biotechnology
application particle design also may need to consider
biological stability of live organisms. The reader is referred
to recent reviews for an introduction into the various
stabilization approaches that have been developed (323) and
the underlying concepts of physical forms of dry dosage forms
(41,314), specifically the nature of amorphous solids (324–
326). This review focuses on the particular issues arising in
stabilization of spray dried microparticles.
Physical stability of microparticles can be accomplished
by designing either a fully crystalline or an amorphous
particle with high viscosity (327). Viscosity in an amorphous
glass is characterized by the glass transition temperature.
Amorphous glasses possess high viscosity if kept well below
the glass transition temperature, which is typically designed to
be 40 to 50°C above the storage temperature. This strategy,
known as glass stabilization, has also been used to provide
chemical stability for the active pharmaceutical ingredient, in
particular for biologicals. Excipients used for glass stabiliza-
tion are usually saccharides, polyols, or organic salts that form
glasses of high viscosity. Embedding molecules in a rigid
amorphous matrix slows degradation reactions by hindering
translational motion, but it may not be sufficient to slow fast
local rotational and vibrational motions of the molecules. A
water replacement strategy may be necessary to achieve
stability (106,328). This strategy uses excipients capable of
replacing the hydrogen bonds that were broken due to
desiccation, or capable of slowing down fast dynamics in
glasses. In case of cell or virus formulations, the situation is
further complicated by the fact that the inside of the organism
can only be protected if stabilizers are transported across its
membrane and the difference between interior and exterior
environment does not cause damage to the integrity of the
cell or virus. Amino acid (35) and saccharide excipients such
as glucose (329), sorbitol (106), lactose (330), sucrose (331–
337), or trehalose (106,125,182,282,283,332,334,337,338) have
been found to be particularly effective in desiccoprotection
and have been used in spray drying applications.
When designing stable microparticles manufactured by
spray drying, one must consider several challenges that are
specific to the microparticle formation process: As discussed
above, components in a microparticle tend to separate due to
their different diffusional velocities if their Peclet numbers
are sufficiently different. It is clearly disadvantageous if
stabilizers separate from the molecule they are supposed to
stabilize. This mechanism has mostly been neglected in
discussions about glass stabilization of microparticles. Rapid Fig. 9. Low density trileucine particles.
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composition is a function of the radius. Hence, the glass
transition temperature is also expected to be different for the
core and the shell of a layered particle (84).
A second mechanism that can lead to unfavorable separa-
tion of components is surface activity. A surfactant that is
successful in keeping air–liquid interface sensitive molecules
awayfromthesurfacemayunintentionallyproduceacoatwitha
low glass transition temperature on the surface that causes
unacceptably high cohesive forces between the particles.
Alternatively, a surface active protein may at least partially be
enriched on the surface, leading to different stabilizer-protein
ratios on the surface versus the core of the particle (131).
A third separation mechanism is the sequential precip-
itation of components due to their different characteristic
times to saturation. The situation is further complicated by
the fact that the precipitation window for typical spray drying
applications is on the order of the characteristic times for
crystal nucleation, crystal growth, or polymorph transitions.
A good example for this effect is the variety of physical
forms of mannitol that have been observed in spray dried
microparticles. Whether mannitol crystallizes during spray
drying or subsequently on storage depends on several factors.
In a salmon calcitonin–mannitol system the mannitol
remained amorphous when the formulation contained less
than 50% mannitol, but crystallized when more mannitol was
added (321). Similar observations were made during the
development of a spray dried monoclonal antibody. Mannitol
crystallinity depended on formulation composition (182) and
crystallization on stability could be retarded by adding an
inhibitor (339). An insulin–mannitol formulation produced
crystalline mannitol, whereas an otherwise similar RNAse-
mannitol formulation produced amorphous mannitol (340).
The sensitivity of the mannitol crystallinity to composition
and processing conditions can be explained by similar
characteristic times for crystallization and droplet evapora-
tion in typical pharmaceutical applications. This hypothesis is
supported by the observation that different polymorphs and
an amorphous mannitol fraction were simultaneously present
in a salmon calcitonin–mannitol formulation at high mannitol
fractions (321,341). According to the Ostwald step rule,
crystallization is initiated by forming the least stable poly-
morph with subsequent transitions to the most stable form.
However, if the process cannot proceed to equilibrium,
because the loss of mobility occurs faster than the transition
to the most stable form, the resulting solid state of the powder
is a mixture of non-equilibrium states, which were arrested
depending on the length of the precipitation window.
Partially crystalline systems or presence of more than
one polymorph has also been observed for other spray dried
substances like glycine (342), sucrose (34), polyethylene
glycol and lactose (343,344), cromolyn sodium (345), or
acetazolamide (346). Particles may also have separated
amorphous phases (347), a possible explanation for the
destabilizing effect of sucrose at high sucrose to protein
ratios. Partially crystalline systems in particular are undesir-
able for two reasons. Firstly, since the more stable solid form
has already been nucleated, the tendency to convert the
remaining less stable fraction during storage is increased. This
may lead to inferior stability. Once the amorphous fraction
starts to crystallize, the water contained in it is mostly
expelled and increases the mobility in the remaining amor-
phous fraction through plasticization. This accelerates the
crystallization (348), which usually causes rapid failure.
Secondly, a solid dosage form whose physical state is sensitive
to small changes in the timing of the drying process is hard to
commercialize. Scale-up becomes very difficult, because the
longer residence time typical for larger dryers is likely to alter
the physical state and, thus the stability of the product (34).
The same mechanisms that lead to the challenges
outlined above present opportunities, which can be exploited
to design structured microparticles with unique properties.
Because of the typically short precipitation window, crystal-
lization of substances during spray drying often leads to very
small crystals. While this can pose a stability risk due to the
tendency of nanocrystals to grow on stability by an Ostwald
ripening mechanism, the unique properties of nanocrystals
can also be beneficial, e.g. leading to an increase in
bioavailability (349) for low solubility molecules. Spatial
separation of material with high and low viscosity can be
used to design structured microparticles that possess much
better physical stability than a homogeneous particle with the
same composition. Typical examples are gel particles, known
as dry emulsions, where liquid nanodroplets are stably
encapsulated in an amorphous matrix with high glass
transition temperature (48,129). Another example of ad-
vanced glass stabilization is shown in Fig. 10. An active
pharmaceutical ingredient with low glass transition tempera-
ture was physically and chemically stabilized in an amorphous,
Fig. 10. Particles designed for high physical stability, containing 56%
of an encapsulation agent forming the shell, 20% saccharide, 20%
active pharmaceutical ingredient with low glass transition tempera-
ture, and 4% inorganic salt.
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the homogeneously mixed formulation was estimated to be
suppressed to approximately 5°C at the 60% RH stress
condition due to plasticization. The storage temperature was
at least 20°C above the glass transition temperature, which in
theory should lead to physical instability of the powder in a
matter of minutes. On the contrary, the aerosol performance
of this powder was still largely unchanged after 7 days of
exposure. The most likely explanation for this observation is
that the particles have a core–shell structure like the one
shown in Fig. 1g. The calculation of the glass transition
temperature assumed a well-mixed glass and a homogeneous
particle, while in reality the particle had a core with low
viscosity encapsulated by a stable shell of high viscosity.
Exceptional physical stability of the powder was the result.
Glass stabilization was introduced to spray dried micro-
particles by Nektar Therapeutics, San Carlos, CA, and
became known under the trademark PulmoSol™ (8,22).
The most prominent product in this category is Exubera
®
(350–352), the first inhalable insulin for the management of
diabetes. The spray dried powder used in Exubera
® consists
of insulin in a buffered formulation of stabilizers. It contains
60% recombinant human insulin, sodium citrate, glycine and
mannitol (12,353). The fully amorphous (354) particles have a
glass transition temperature of approximately 115°C when
completely dry, and of 78–95°C when the moisture content is
within storage specifications (351). Physical and chemical
stability is excellent, providing 2 years of shelf life at room
temperature (355). Comparing the molecular weights of the
excipients shows that insulin has the highest Peclet number in
this formulation. Considering its high initial concentration in
the formulation, the theory presented in this review predicts
that insulin is the main shell former and the particles will
likely have the typical wrinkled or dimpled protein
morphology. Indeed, the Exubera powder morphology
shows external voids on particles with a folded shell (351,
356) and is nearly identical to that of pure spray dried
insulin (112). These particles have been thoroughly tested in
various human trials during the development of Exubera
®.
Pharmacology, efficacy and safety of the product have been
reviewed extensively (9,27,355,357,358).
Outlook
The examples given in this review show the level of
sophistication that can be achieved with a seemingly simple
process such as spray drying. Even spray drying from a
homogeneous solution, if properly understood, can be used to
design particles that have a multifunctional internal structure.
Potential further advances in particle engineering may be
achieved by combining spray drying with additional process-
ing steps before, during, or after the drying step.
The most common modification to a simple solution
spray drying process is the preparation of a suspension or
colloid prior to spray drying. Two-phase systems are often
necessary because of solubility limitations of active and
excipients, but they are also employed to transfer some of
the structural properties of the two-phase system onto the
final dry particles. A typical example is spray drying from an
o/w emulsion to manufacture PulmoSpheres™, where the
droplet size of the dispersed phase influences the void size in
the dried particles. Ordinary emulsions, mostly o/w emulsions
(46–48), and immiscible aqueous (359) and non-aqueous
(360) two-phase systems have been studied. Multiple emul-
sions have also been successfully spray dried, e.g. an O/W/O/
W triple emulsion for the encapsulation of orange oil (361).
Spray drying of sols (362–365) or suspended solids is a
variation of this theme.
Again,theuseofasoliddispersionisoftendictatedbypoor
solubility and the dispersed solid may simply be micronized or
unprocessed material (366–371). Increasingly, though, the
dispersed phase has been produced in yet another processing
step and possesses specific properties that translate to the final
dried particle. Dispersions of small unilamellar liposomes have
been spray dried to produce highly dispersible powders for
possible pulmonary delivery of superoxide dismutase (372).
Spray dried suspensions of dextran microspheres (373)w e r e
investigated in the context of nasal drug delivery, pre-formed
microcapsules were spray dried to encapsulate phase change
materials (374), and dispersions of porous and non-porous
silica micro and nanoparticles were spray dried in combination
with indomethacin (375), tolbutamide (376), and simvastatin
(377). DNA in combination with lyoprotectants was lyophi-
lized, micronized, and subsequently spray dried as a solid-in-oil
dispersion to achieve encapsulation in PLGA (378).
A very exciting development is the design of compos-
ite particles spray dried from dispersed nanoparticles
(51,52,70,73,86,119,365,379–384) or even mixtures of different
nanoparticles (385). The nanoparticles are typically manufac-
tured separately prior to preparation of the dispersion and retain
their special properties such as enhanced solubility or targeting
capacity for the final product. Some of their disadvantages, e.g.
their tendency to agglomerate or their unfavorable aerosol
transport properties, are mitigated by the fact that they are now
part of a larger microparticle (382). It is interesting that the
properties of the product are now determined by the primary
m o r p h o l o g yo ft h ec o m p o s i t ep a r t i c l e ,t h em o r p h o l o g yo fi t s
nanoscale substructure, and their interactions. This highlights
the importance of proper particle design in these systems.
Rather complex dispersion systems with more than one
solid dispersed phase have been studied. Calcium salts were
dispersed in an aqueous polymeric suspension and then spray
dried to produce microencapsulated particles (386). A second
example with multiple pre-processing steps is based on a
complex dispersion of polymer nanoparticles and micronized
fumed silica that was spray dried to produce nanoparticle-
coated microparticles (387–393). In this system the drug may
be associated either with the organic nanoparticle phase or
the inorganic silicon dioxide phase. Several complex disper-
sions based on o/w emulsions with additional suspended solid
material have also been tried. The solid dispersed phase
consisted either of the micronized active (181,184), precipi-
tated ethylcellulose (216), or highly porous magnesium
aluminometasilicate particles (394).
In the second class of modified spray drying additional
steps are added during atomization or drying. Typical
examples are atomizer nozzles that allow the mixing of fluids
immediately prior to or simultaneous with the atomization
process (395,396), or multi-zonal drying chambers, where the
droplet evaporation is followed by a secondary drying or firing
step that can change the solid state of the particles (397)o r
remove placeholder material to create porosity (382,398,399).
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dispersions is coupled with a multi-zonal dryer with three
different temperature zones have been presented (400).
Lastly, post-processing steps can be added after spray
drying.Whilesecondarydryingiscommontoadjustthemoisture
content of powder, more intricate processes such as microen-
capsulation (401) have also been proposed. Developments in
the area of bioactive surface layers seem particularly promising.
For example, the surface of spray dried microparticles has been
loaded with covalently bonded antibodies (402) or adsorbed
DNA (403,404) for immunomodulation purposes.
A thorough review of the large number of combination
processes where spray dried microparticles play a role is
beyond the scope of this review. It will be interesting to follow
whether the added functionality of the particles fabricated
with such processes will justify their increased complexity in a
commercial setting. It is already obvious that the new class of
engineered spray dried particles requires a shift in the
thinking and structure of pharmaceutical organizations devel-
oping them. Because both process and formulation now equally
determine key product parameters, it should be reconsidered
whether separate groups working on formulation and process
development, optimization and scale-up are adequate. This new
class of products demands a unified design approach reflected in
an organizational structure that allows constant collaboration of
formulators and process engineers in a single group. It also
becomes evident that purely empirical approaches to product
design are doomed to fail in a situation where the parameter
space is defined by a very large number of formulation and
process variables. Successful design of engineered particles
requires thorough understanding and predictive modeling, so
that the early development process can be completed in an
acceptable time with a high likelihood of success. Much of the
fundamental work, including the measurement of urgently
needed material properties remains to be done.
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